atopic


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.

a·top·ic

 (ā-tŏp′ĭk)
adj.
Of, relating to, or caused by a hereditary predisposition to developing allergic reactions, such as hay fever, asthma, or urticaria, after exposure to specific antigens such as pollen, food, and insect venoms.

[From Greek atopiā, unusualness, from atopos, out of the way : a-, not; see a-1 + topos, place.]

at′o·py (ăt′ə-pē) n.

atopic

(əˈtɒpɪk)
adj
(Physiology) immunol of or relating to hereditary hypersensitivity to certain allergens
Translations

a·top·ic

a. atópico-a, rel. a la atopía.

atopic

adj atópico
References in periodicals archive ?
A pivotal Phase 3 trial evaluating Dupixent[R] (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints.
In this clinical trial, weekly subcutaneous, or SC, doses of KPL-716 resulted in a rapid and sustained reduction in pruritus throughout the 12-week treatment period but also a higher rate of atopic dermatitis flares.
ENPNewswire-August 7, 2019--Sanofi - Dupixent showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
M2 PHARMA-August 6, 2019-Regeneron Pharmaceuticals Inc announces EC marketing approval for Dupixent (dupilumab) for moderate-to-severe atopic dermatitis
Global Banking News-August 6, 2019-Regeneron Pharmaceuticals Inc announces EC marketing approval for Dupixent (dupilumab) for moderate-to-severe atopic dermatitis
M2 EQUITYBITES-August 6, 2019-Regeneron Pharmaceuticals Inc announces EC marketing approval for Dupixent (dupilumab) for moderate-to-severe atopic dermatitis
CHICAGO -- Atopic dermatitis in adulthood was associated with a twofold increase in the risk of developing dementia late in life, based on results from a large longitudinal cohort study presented at the annual meeting of the Society for Investigative Dermatology.
Atopic dermatitis is a very common inflammatory skin disease whose incidence is increasing worldwide and which has a significantly negative effect on the quality of life.
"The data presented at AAD 2019 build upon the established body of knowledge around the efficacy and safety of Dupixent, which has been used to treat nearly 50,000 patients with inadequately controlled moderate-to-severe atopic dermatitis since its approval nearly two years ago," said Neil Graham, M.D., Vice President of Program Direction at Regeneron.
Atopic dermatitis, also called atopic eczema, is one such skin condition that affects one in five children globally.
Objective: To compare the efficacy and safety of topical betamethasone valerate 0.1% with narrowband ultraviolet B (NB-UVB) therapy in atopic dermatitis.